Prohibits the use of fetal organs or tissue resulting from abortions for medical, scientific, research, experimental, or therapeutic purposes or any other use
HB1246 repeals and replaces Missouri’s existing section 188.036 to create a broader prohibition on the use of fetal organs or tissue resulting from abortions. The bill bars physicians from performing an abortion if they know the pregnancy was conceived for the purpose of obtaining fetal organs or tissue for transplantation, and it also prohibits anyone from using fetal organs or tissue from an abortion for medical transplantation when they know the abortion was procured for that purpose.
The bill further makes it unlawful to offer or receive inducements or valuable consideration in connection with conceiving a child or procuring an abortion for the medical, scientific, experimental, or therapeutic use of fetal tissue. It also expressly prohibits any person or entity from using fetal organs or tissue resulting from an abortion for medical, scientific, research, experimental, therapeutic, or any other use, while preserving exceptions for burial, final disposition, and pathological, autopsy, or postmortem examination costs. A severability clause is included so that if part of the section is invalidated, the rest can remain in effect.
HB1246 would significantly tighten Missouri law governing fetal tissue and organ use by expanding restrictions beyond transplantation to include research, experimental, therapeutic, and any other use. It would amend state abortion-related statutes by adding new prohibitions on physicians, individuals, and entities involved in fetal tissue procurement, transfer, or use, and it would reinforce criminal or regulatory exposure for conduct involving inducements or compensation tied to fetal tissue. The bill would primarily affect abortion providers, medical researchers, tissue users, and any organization handling fetal remains.
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the measure appears to reflect a strongly restrictive, anti-fetal-tissue-use policy position. The language is categorical and expansive, suggesting support from lawmakers seeking to prevent any commercial, scientific, or therapeutic use of fetal tissue derived from abortion. No contrary arguments or amendments are shown in the available record, so the overall sentiment in the provided context is one of prohibition and deterrence rather than compromise.
The main points of contention likely center on the bill’s broad ban on fetal tissue use for research and therapeutic purposes, which could affect biomedical research, transplantation, and medical innovation. Another likely dispute is the prohibition on inducements or compensation, which may be viewed by supporters as preventing exploitation but by critics as unnecessarily sweeping and potentially impeding legitimate medical or scientific work. The bill also raises practical questions about enforcement and how to distinguish prohibited uses from permitted pathology, autopsy, or burial-related activities.